Skip to main content
Explore URMC

menu

Lung Cancer (NSCLC): A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

Research Question:
What are the effects of the study drugs, lorlatinib when given alone to crizotinib given alone and which is better for treating ALK-positive NSCLC?

Basic Study Information

Purpose:
If you participate in this research study, you will be assigned by chance (like flip of a coin or drawing straws) to receive either lorlatinib alone (Group A) or crizotinib alone (Group B). You will have a 50% (1 in 2) chance of receiving lorlatinib, and a 50% (1 in 2) chance of receiving crizotinib. Neither you nor your doctor can choose the group you will be in.

Location: Cancer Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT03052608?term=B7461006&rank=1
Study Reference #: ILUN17067

Lead Researcher (Principal Investigator)

Lead Researcher: Megan Baumgart

Study Contact Information

Study Coordinator: Amy Jasek
Phone: (585) 273-1912
Email: Amy_Jasek@URMC.Rochester.edu

Additional Study Details

Learn More About These Conditions

More information about Lung Cancer

Return to Search